clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Tuberculosis, Spinal D014399 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Monno R et al. Chlamydia trachomatis and Mycobacterium tuberculosis lung infection in an HIV-positive homosexual man. 2001 AIDS Patient Care STDS pmid:11788074
Yangco BG et al. Is primary mycobacterium avium complex prophylaxis necessary in patients with CD4 <50 cells/μL who are virologically suppressed on cART? 2014 AIDS Patient Care STDS pmid:24833016
Aboulafia DM Thalidomide-based treatment for HIV-associated multiple myeloma: a case report. 2003 AIDS Read pmid:14524324
Kahlon SS et al. Mycobacterium-avium-intracellulare complex immune reconstitution inflammatory syndrome in HIV/AIDS presenting as osteomyelitis. 2008 AIDS Read pmid:18975441
Chu J et al. Drug efficacy by direct and adjusted indirect comparison to placebo: An illustration by Mycobacterium avium complex prophylaxis in HIV. 2011 AIDS Res Ther pmid:21388558
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Kihira K et al. Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection. 2000 Aliment. Pharmacol. Ther. pmid:10930904
Kamada T et al. Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of helicobacter pylori in smokers. 2000 Aliment. Pharmacol. Ther. pmid:10930905
Nagahara A et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. 2001 Aliment. Pharmacol. Ther. pmid:11207518
Bardhan KD et al. Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. 2000 Aliment. Pharmacol. Ther. pmid:10632646
Calvet X et al. One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. 2002 Aliment. Pharmacol. Ther. pmid:12144575
Spinzi GC et al. Comparison of omeprazole and lansoprazole in short-term triple therapy for Helicobacter pylori infection. 1998 Aliment. Pharmacol. Ther. pmid:9663722
O'Connor HJ et al. Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? 1998 Aliment. Pharmacol. Ther. pmid:9570262
Goodgame RW et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. 2001 Aliment. Pharmacol. Ther. pmid:11736715
De Francesco V et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. 2004 Aliment. Pharmacol. Ther. pmid:15113366
Gisbert JP and Calvet X Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. 2011 Aliment. Pharmacol. Ther. pmid:22017749
Pellegrini M et al. Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. 2005 Aliment. Pharmacol. Ther. pmid:16098001
Huang J and Hunt RH Clarithromycin-based triple therapies. 1999 Aliment. Pharmacol. Ther. pmid:10102978
Osato MS et al. Comparative efficacy of new investigational agents against Helicobacter pylori. 2001 Aliment. Pharmacol. Ther. pmid:11284777
Klok RM et al. Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs. 2002 Aliment. Pharmacol. Ther. pmid:11966514